Abstract
An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.
| Original language | English |
|---|---|
| Journal | American Journal of Surgery |
| Volume | 184 |
| Issue number | 6 SUPPL. 1 |
| State | Published - Dec 1 2002 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
Risk-benefit analysis for drotrecogin alfa (activated). / Schein, Roland; Kinasewitz, Gary T.
In: American Journal of Surgery, Vol. 184, No. 6 SUPPL. 1, 01.12.2002.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Risk-benefit analysis for drotrecogin alfa (activated)
AU - Schein, Roland
AU - Kinasewitz, Gary T.
PY - 2002/12/1
Y1 - 2002/12/1
N2 - An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.
AB - An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.
UR - http://www.scopus.com/inward/record.url?scp=0036939294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036939294&partnerID=8YFLogxK
M3 - Article
C2 - 12521615
AN - SCOPUS:0036939294
VL - 184
JO - American Journal of Surgery
JF - American Journal of Surgery
SN - 0002-9610
IS - 6 SUPPL. 1
ER -